Aztreonam Combination Therapy: An Answer to Metallo-β-Lactamase-Producing Gram-Negative Bacteria?
Published in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
A First-in-Human Study To Assess the Safety and Pharmacokinetics of LYS228, a Novel Intravenous Monobactam Antibiotic in...
Published in Antimicrobial Agents and Chemotherapy
Infections caused by antibiotic-resistant Gram-negative bacteria expressing extended-spectrum β-lactamases and carbapenemases are a growing global problem resulting in increased morbidity and mortality with limited treatment options. LYS228 is a novel intravenous monobactam antibiotic targeting penicillin binding protein 3 with potent activity agai...
Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing...
Published in Antimicrobial Agents and Chemotherapy
Metallo-β-lactamase (MBL)-producing Gram-negative bacteria are often extremely resistant, leading to a real therapeutic dead end. Here, we evaluated the in vitro and in vivo efficacy of aztreonam in combination with ceftazidime-avibactam, ceftolozane-tazobactam, or amoxicillin-clavulanate for the treatment of infections caused by MBL-producing Ente...
Mode of Action of the Monobactam LYS228 and Mechanisms Decreasing In Vitro Susceptibility in Escherichia coli and Klebsi...
...Published in Antimicrobial Agents and Chemotherapy
The monobactam scaffold is attractive for the development of new agents to treat infections caused by drug-resistant Gram-negative bacteria because it is stable to metallo-β-lactamases (MBLs). However, the clinically used monobactam aztreonam lacks stability to serine β-lactamases (SBLs) that are often coexpressed with MBLs. LYS228 is stable to MBL...
3rd Generation of Cephalosporins and Monobactam Resistant Among Pathogenic Bacteria Collected from Ilam Hospitals During...
Published in Recent patents on anti-infective drug discovery
Recently, increasing antibiotic resistance is causing serious publichealth concerns worldwide. This phenomenon increased patient's morbidity and mortality rate, particularly in immunocompromised individuals. Considering that antimicrobial resistance can vary according to geographical location, we investigated the status of antibiotic resistance in ...
Therapeutic Drug Monitoring of Prolonged Infusion Aztreonam for Multi-Drug Resistant Pseudomonas aeruginosa: A Case Repo...
Published in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
Aztreonam, a broad-spectrum monobactam, is typically reserved for multidrug resistant (MDR) infections. Pharmacokinetic (PK) data to guide dosing in children, however, are limited to healthy volunteers or nonintensive care unit (ICU) patients. Impaired antibiotic delivery into tissue remains a major concern and may explain the high morbidity and mo...
Management of allergy to penicillins and other beta-lactams.
...Published in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
The Standards of Care Committee of the British Society for Allergy and Clinical Immunology (BSACI) and an expert panel have prepared this guidance for the management of immediate and non-immediate allergic reactions to penicillins and other beta-lactams. The guideline is intended for UK specialists in both adult and paediatric allergy and for other...
Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis.
Published in P & T : a peer-reviewed journal for formulary management
We sought to evaluate the pharmacokinetics, efficacy, safety, stability, pharmacoeconomics, and quality-of-life effects of continuous-infusion antipseudomonal beta-lactam therapy in patients with cystic fibrosis (CF). Literature retrieval was accessed through Medline (from 1950 to December 2010) using the following terms: cystic fibrosis; beta-lact...
Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam d...
...Published in ACS medicinal chemistry letters
A novel series of monocarbam compounds exhibiting promising antibacterial activity against multidrug resistant Gram-negative microorganisms is reported, along with the synthesis of one such molecule MC-1 (1). Also reported are structure-activity relationships associated with the in vitro and in vivo efficacy of 1 and related analogues in addition t...
